Entinostat

恩替司他

Report date: 2026/04/21 20:00:18
NME

Base Information

Drug NameEntinostat
Drug Alias Name恩诺司他Entinostatum恩替司他恩替诺特景助达 +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone deacetylase 2 inhibitorsHistone deacetylase 3 inhibitorsHistone deacetylase 1 inhibitors
TargetsHistone deacetylase 2Histone deacetylase 1Histone deacetylase 3
Therapy Area/IndicationsUveal melanomaBrain metastasesMetastatic breast cancer +[92] 
Global Approved IndicationsMetastatic breast cancerBreast Neoplasms
Approved Indications in ChinaMetastatic breast cancerBreast Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2024/04/24
Country/TerritoryCzechiaCanadaUnited States +[12] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBayer AG
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesNational Cancer InstituteSyndax Pharmaceuticals IncUniversity Of Virginia +[5] 
Inactive CompaniesKyowa Kirin Co LtdNational Institutes Of Health Clinical Center (Cc)University Of Maryland, Baltimore +[6] 
Active IndicationsUveal melanomaBrain metastasesMetastatic breast cancer +[30] 
Inactive IndicationsAngioimmunoblastic T-cell LymphomaCentral Nervous System LymphomaBreast Diseases +[62] 

Other Information

ATC CodeL01XH05
Related LinksWikipediaDrugBankKEGG